We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Xi'an Tianlong Science & Technology Co., Ltd

Tianlong is an innovative, high-technology company that provides professional PCR detection devices, reagent kits and... read more Featured Products: More products

Download Mobile App




TianLong Participated in the International Medical Congress of SCO Countries in Kyrgyzstan

By LabMedica International staff writers
Posted on 16 Apr 2024
Print article
TianLong Participated in the International Medical Congress of SCO Countries in Kyrgyzstan (photo courtesy of Tianlong)
TianLong Participated in the International Medical Congress of SCO Countries in Kyrgyzstan (photo courtesy of Tianlong)
The International Medical Congress of the SCO countries kicked off in Bishkek, Kyrgyzstan on March 27-29 under the topic “Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai Cooperation Organization.” TianLong Science and Technology Co., Ltd. was invited to attend and deliver a speech at the Congress, showcasing and discussing its latest achievements and innovations in the fields of personalized medication and laboratory medicine with top experts.

Minister of Health of the Kyrgyz Republic Alymkadyr Beishenaliev, Deputy Secretary General of the SCO Janesh Kane, as well as 400 medical staff and representatives of medical organizations, including more than 100 foreign guests, academicians and world-famous scientists, took part in the Congress, dedicated to the memory of the outstanding scientist and clinician, academician Mirsaid Mirrakhimov.

At this Congress, Tianlong invited Professor Kou Huijuan from the Department of Cardiology at the Second Affiliated Hospital of Xi'an Jiaotong University to deliver a speech. During the speech, Professor Kou discussed the precise treatment and current progress of hypertension diagnosis and treatment in China, as well as a series of clinical cases. Professor Kou also shared Tianlong's personalized medication solution of hypertension, which can detect seven gene mutations in hypertension medication and guide five types of hypertension medication. She introduced that “Personalized medication is a new medical model that can determine the dosage and type of drugs for each patient based on genetic differences. We have developed from general therapy to individualized medication”, which has brought valuable inspiration to the attendees.

Tianlong was also invited to join in a series of conferences and exchanges in Kyrgyzstan. At an international conference on “Topical issues of laboratory medicine”, Jessica Wu(PhD of Molecular Biology) from Tianlong’s Overseas Marketing Dept, delivered a speech about “LigSeq Reagent Kit - Tianlong's personalized medication solutions”. During the presentation, Dr. Wu discussed the significance of personalized medication and shared the latest research and application cases. She introduced that “Tianlong's personalized medication solution can detect genes related to the effects of commonly used drugs for diseases, providing guidance for clinical treatment.” The presentation has generated widespread interest and discussion among the attending experts.

In addition, Professor Kou and Dr. Wu were invited to give lectures at the Sixth State Hospital in Bishkek, as well as at the local cardiac surgery clinic and medical centre. During the series of lectures, they shared the latest medical technologies and research on hypertension, and also engaged in technical exchanges, which were welcomed by the local medical staff and built a solid bridge for international exchange and cooperation.

LigSeq Reagent Kit
Tianlong Personalized Medication Solutions

Tianlong's personalized medication solutions, including a series of detection instrument and reagents, can detect genes related to the effects of commonly used drugs for assisted reproduction, endocrine drugs, as well as cardiovascular, digestive, psychiatric, rheumatic immunity, oncology and other diseases, providing guidance for clinical treatment.

It has the advantages of rapid detection, accurate results, comprehensive reports and user-friendly.

Through these medical conferences, Tianlong showcased its innovations and research achievements in laboratory medicine and personalized medication. The conferences also facilitated international exchanges and cooperation in the medical field. In the future, Tianlong will continue its commitment to scientific research, innovation, and technological development for the global advancement of medicine and healthcare.

For more information or inquiries, please contact Tianlong team directly.


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.